Hydroflumethiazide

Thông tin thuốc gốc
Chỉ định và Liều dùng
Oral
Oedema
Adult: In cases of cardiac, renal or hepatic origin, including iatrogenic oedema: Initially, 50-200 mg daily in 1 or 2 divided doses, preferably in the morning, may reduce to 25-50 mg on alternate days or intermittently according to patient’s response.
Elderly: Dose reduction may be required.
Child: >12 years Recommended dose: Initially, 1 mg/kg daily.

Oral
Hypertension
Adult: As monotherapy or in combination with other antihypertensive agents: Usual dose: 25-50 mg daily. Maintenance: 25-50 mg on alternate days.
Elderly: Dose reduction may be required.
Child: >12 years Recommended dose: Initially, 1 mg/kg daily.
Suy thận
Severe: Contraindicated.
Suy gan
Severe: Contraindicated.
Chống chỉ định
Addison’s disease, hypercalcaemia, symptomatic hyperuricaemia, refractory hypokalaemia, hyponatraemia, anuria. Severe renal and hepatic impairment. Concomitant use with lithium.
Thận trọng
Patient with diabetes, gout, or SLE. Children and elderly. Pregnancy and lactation.
Tác dụng không mong muốn
Significant: May aggravate diabetes, gout or SLE; hypokalaemia.
Blood and lymphatic system disorders: Blood dyscrasias
Gastrointestinal disorders: Pancreatitis, diarrhoea.
Hepatobiliary disorders: Intrahepatic cholestasis.
Immune system disorders: Hypersensitivity reactions.
Investigations: Altered plasma lipid concentrations.
Metabolism and nutrition disorders: Hyponatraemia, hypercalcaemia, hypochloraemic alkalosis, hyperuricaemia, hyperglycaemia.
Reproductive system and breast disorders: Impotence.
Skin and subcutaneous tissue disorders: Rash, photosensitivity.
Vascular disorders: Postural hypotension.
Chỉ số theo dõi
Monitor renal function; electrolyte levels and signs of blood dyscrasias (prolonged use, particularly in elderly).
Quá liều
Symptoms: Diuresis, lethargy (progressing to coma, with minimal cardiorespiratory depression and with or without significant serum electrolyte changes or dehydration), gastrointestinal irritation, hypermotility, transient elevation of BUN level. Management: Symptomatic and supportive treatment. Empty stomach by gastric lavage. Institute supportive measures as required to maintain hydration, electrolyte balance, respiration, and cardiovascular and renal function.
Tương tác
May increase sensitivity to and risk of toxicity of digitalis. May result in antagonistic effect with NSAIDs (e.g. indometacin, ketorolac), corticosteroids, estrogens and combined oral contraceptives. Enhanced hypotensive effect with ACE inhibitors, angiotensin II antagonists, β-blockers, Ca channel blockers, nitrates, adrenergic neurone blockers, general anaesthetics, anxiolytics, hypnotics, MAOI, phenothiazines, alprostadil, aldesleukin, levodopa, baclofen, moxisylyte, tizanidine, and α-blockers (e.g. prazosin). Increased risk of nephrotoxicity and ototoxicity with cisplatin. May exacerbate hypokalaemia with acetazolamide, corticosteroids, amphotericin, reboxetine, β2 sympathomimetics, theophylline, and loop diuretics. Increased risk of nephrotoxicity and hypermagnesaemia with ciclosporin. Increased cardiotoxicity with disopyramide, amiodarone, cardiac glycosides, flecainide, quinidine. Antagonise effects of lidocaine, mexiletine and antidiabetic agents. Increased risk of ventricular arrhythmias with amisulpride, sotalol, atomoxetine, sertindole, terfenadine. May increase risk of postural hypotension with TCAs. May increase the risk of hypersensitivity with allopurinol. May increase risk of lithium toxicity. May reduce absorption with colestipol and colestyramine. Increased risk of hyponatraemia with aminoglutethimide, carbamazepine, chlorpropamide. Increased the risk of hypercalcaemia with calcium salts, toremifene and vitamin D.
Tương tác với thức ăn
Increased risk of postural hypotension with alcohol.
Tác dụng
Description:
Mechanism of Action: Hydroflumethiazide is a thiazide diuretic that acts mainly on the distal convoluted tubule to the thick segment of the end limb of the loop of Henle. It inhibits the distal tubular re-absorption of Na and Cl ions resulting in increased urinary loss of K and Mg. Additionally, it increases the renal tubular re-absorption of Ca.
Onset: Approx 2 hours.
Duration: Up to 24 hours.
Pharmacokinetics:
Absorption: Rapidly but incompletely absorbed from the gastrointestinal tract. Time to peak plasma concentration: Approx 1-4 hours.
Distribution: Volume of distribution: 6.4 L/kg. Plasma protein binding: Approx 75%.
Excretion: Via urine (40-80% as unchanged drug). Plasma elimination half-life: 12.4-26.9 hours.
Đặc tính

Chemical Structure Image
Hydroflumethiazide

Source: National Center for Biotechnology Information. PubChem Database. Hydroflumethiazide, CID=3647, https://pubchem.ncbi.nlm.nih.gov/compound/3647#section=2D-Structure&fullscreen=true

Bảo quản
Store below 25°C.
Phân loại MIMS
Thuốc lợi tiểu
Phân loại ATC
C03AA02 - hydroflumethiazide ; Belongs to the class of low-ceiling thiazide diuretics.
Tài liệu tham khảo
Buckingham R (ed). Hydroflumethiazide. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 09/06/2021.

Neo-Urizide Tablets (Chelonia Healthcare Limited). MHRA. https://products.mhra.gov.uk. Accessed 09/06/2021.

Saluron Tablet (Shire). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 22/06/2021.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Hydroflumethiazide từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2026 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com